NASHVILLE, TN (WSMV) - As U.S. officials warn that the pace of vaccinations across the country has been too slow, early results are showing that a single-shot vaccine from Johnson & Johnson could be a promising candidate. 

Unlike the Pfizer and Moderna vaccines, which require two doses, Johnson & Johnson's would require only one to create an effective immune response. 

The company gave healthy adults between ages 18 and 55 and people over 65 a high or low dose of the vaccine or a placebo. 

After 28 days, most of the volunteers had produced detectable antibodies. After 57 days, all volunteers had detectable antibodies, regardless of the size of the vaccine dose or age group. 

Scientists with Johnson & Johnson say the Phase One and Two clinical trial data suggests a single dose of the vaccine gives sustainable antibodies against the coronavirus. 

Johnson & Johnson is expected to release results from its 45,000-person Phase Three trial later this month. 

If the company's vaccine is authorized by the FDA it would become the third approved for use in the United States. 

 
 

WSMV.com is now with you on the go! Get the latest news updates and video, 4WARN weather forecast, weather radar, special investigative reports, sports headlines and much more from News4 Nashville.

>> Click/tap here to download our free mobile app. <<


Copyright 2020 WSMV (Meredith Corporation). All rights reserved.

 

Recommended for you

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.